Table 2.
Cell cycle analysis of MDA-MB-231 cells after treatment for 24 h showing the DNA content (mean ± SEM) at different cycle phases
| Drug | Cell cycle phases | |||
|---|---|---|---|---|
| SubG0/G1 | G0/1 | S | G2/M | |
| Control | 9.8 ± 0.30 | 50.95 ± 1.15 | 12.70 ± 0.70 | 26.45 ± 2.15 |
| Dox | 13.35 ± 0.35 | 38.40 ± 3.90 | 17.95 ± 1.45 | 29.3 ± 3.10 |
| Cyclo | 9.50 ± 0.10 | 45.85 ± 1.95 | 17.85 ± 0.35 | 26.45 ± 2.35 |
| Pitavastatin | 18.90 ± 0.60 | 57.10 ± 1.7 | 21.55 ± 1.65 | 1.25 ± 1.15 |
| Simvastatin | 22.35 ± 1.05 | 43.25 ± 2.05 | 33.20 ± 3.40 | 1.85 ± 1.25 |
| Dox/ cyclo | 20.20 ± 0.30 | 44.75 ± 0.75 | 3.35 ± 0.05 | 33.85 ± 0.65 |
| Dox/ cyclo + Pitavastatin | 22.7 ± 0.70 | 64.35 ± 1.05 | 4.350 ± 0.45 | 10.90 ± 1.40 |
| Dox/ cyclo + simvastatin | 29.05 ± 1.85 | 61.85 ± 1.85 | 3.05 ± 0.35 | 9.05 ± 1.55 |
G0/G1: growth phase 0/1, S: synthesis phase, G2/M: growth phase 2 and mitosis phase. Control sets as untreated cells; Dox: doxorubicin (6.25 µg/ml) in MDA-MB-231, Cyclo: cyclophosphamide (100 µM), Pitavastatin (50 µM), simvastatin (25 µM).